Therefore, we tested the effects of Yod1 overexpression in an Alzheimer’s disease (AD) model, which is based on the expression of human amyloid beta peptide (Aβ, amino acids 1–42)19. This evidence concerns the gene APP and early-onset autosomal dominant Alzheimer disease.